Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Intensity Therapeutics, Inc.

Intensity Therapeutics is a biotechnology company focused on developing novel intratumoral cancer treatments that aim to kill tumors and activate a systemic immune response.

Intensity Therapeutics

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases.

Intensity is based in Westport, Connecticut. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.

VCapital

SalvaRx Group PLC

Batterson Venture Capital

Declan Doogan

Jim Mellon

Starting off the year at #JPM24, we’re excited to announce our “Study May Proceed” letter from the #FDA for our Phase 3 trial using our lead #cancer drug product candidate, INT230-6 for the treatment of metastatic #sarcoma. Our latest update: https://bit.ly/3NOLrxT

AT #SABCS23, Intensity presented positive safety, tolerability, efficacy and immune activation data from the Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage #breastcancer in a podium spotlight discussion. Full press release: https://bit.ly/3Tcm0dn

We are excited to continue delivering promising results with our drug, INT230-6.

Intensity is proud to have created technology that benefits people, has treated many people so far and continues to get results to advance cancer treatment.

The Intensity Therapeutics team rang the Closing Bell at Nasdaq last week in New York! Thank you for supporting our mission to help patients live longer, higher quality lives by developing cancer therapies designed to kill tumors and increase immune system recognition.

Welcome Joe Talamo to Intensity as Chief Financial Officer! With over 25 years of financial strategies expertise in the space, Joseph will be integral to our team as we advance our lead asset INT230-6 for the treatment of #solidtumors. Learn more: https://bit.ly/46Ubj2f

NASDAQ:INTS